Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review.
Gespeichert in:
| Titel: | Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review. |
|---|---|
| Autoren: | McKoy K; Dynavax Technologies Corporation, Emeryville, CA, USA., Campbell S; Dynavax Technologies Corporation, Emeryville, CA, USA., Novy P; Dynavax Technologies Corporation, Emeryville, CA, USA., Janssen RS; Dynavax Technologies Corporation, Emeryville, CA, USA. |
| Quelle: | Expert review of vaccines [Expert Rev Vaccines] 2025 Dec; Vol. 24 (1), pp. 365-372. Date of Electronic Publication: 2025 May 12. |
| Publikationsart: | Journal Article; Review; Comparative Study |
| Sprache: | English |
| Info zur Zeitschrift: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Future Drugs Ltd., 2002- |
| MeSH-Schlagworte: | Hepatitis B Vaccines*/administration & dosage , Hepatitis B Vaccines*/immunology , Hepatitis B Vaccines*/adverse effects , HIV Infections*/complications , HIV Infections*/immunology , Hepatitis B*/prevention & control, Humans ; Vaccination/methods ; Immunization Schedule ; Coinfection ; Adjuvants, Immunologic/administration & dosage |
| Abstract: | Introduction: To eliminate hepatitis B virus (HBV) globally, a key focus is preventing new infections among high-risk individuals, including those with HIV. The widespread incidence of HBV and HIV leads to a high rate of coinfection. HIV compromises the immune system, significantly increasing the risk of chronic HBV infection, cirrhosis, liver cancer, and death from liver-related disease among coinfected individuals. Areas Covered: This review explores recent research on the two-dose HepB-CpG (HEPLISAV-B) vaccine, which is a potential solution to the challenge of suboptimal immune responses to three-dose HBV vaccines (HepB-alum) in people living with HIV (PLWH). We compare the immunogenicity and safety of HepB-CpG in both vaccine-naive and previously vaccinated nonresponding PLWH populations. Expert Opinion: Compared with three-dose HepB-alum vaccines, HepB-CpG offers a more convenient two-dose schedule, which could increase series completion rates. HepB-CpG might be more immunogenic in vaccine-naive and vaccine-experienced PLWH. Both attributes make HepB-CpG a possible future standard of care for adult HBV vaccination in PLWH. |
| Contributed Indexing: | Keywords: CpG 1018 adjuvant; HEPLISAV-B; HIV infection; HepB-CpG; HepB-alum; hepatitis B virus; immunogenicity; safety |
| Substance Nomenclature: | 0 (Hepatitis B Vaccines) 0 (Adjuvants, Immunologic) |
| Entry Date(s): | Date Created: 20250508 Date Completed: 20250512 Latest Revision: 20250526 |
| Update Code: | 20250526 |
| DOI: | 10.1080/14760584.2025.2502643 |
| PMID: | 40336183 |
| Datenbank: | MEDLINE |
Nájsť tento článok vo Web of Science | Abstract: | Introduction: To eliminate hepatitis B virus (HBV) globally, a key focus is preventing new infections among high-risk individuals, including those with HIV. The widespread incidence of HBV and HIV leads to a high rate of coinfection. HIV compromises the immune system, significantly increasing the risk of chronic HBV infection, cirrhosis, liver cancer, and death from liver-related disease among coinfected individuals.<br />Areas Covered: This review explores recent research on the two-dose HepB-CpG (HEPLISAV-B) vaccine, which is a potential solution to the challenge of suboptimal immune responses to three-dose HBV vaccines (HepB-alum) in people living with HIV (PLWH). We compare the immunogenicity and safety of HepB-CpG in both vaccine-naive and previously vaccinated nonresponding PLWH populations.<br />Expert Opinion: Compared with three-dose HepB-alum vaccines, HepB-CpG offers a more convenient two-dose schedule, which could increase series completion rates. HepB-CpG might be more immunogenic in vaccine-naive and vaccine-experienced PLWH. Both attributes make HepB-CpG a possible future standard of care for adult HBV vaccination in PLWH. |
|---|---|
| ISSN: | 1744-8395 |
| DOI: | 10.1080/14760584.2025.2502643 |